Health & Environment
ICMR Licenses SHetA2 Pill for Cervical Cancer Treatment
Deccan Herald1h
THE BRIEF
1
The Indian Council of Medical Research (ICMR) has licensed the anti-HPV therapeutic candidate SHetA2 to Emcure Pharmaceuticals to develop a non-surgical treatment for cervical intraepithelial neoplasia.
2
The small molecule therapy targets proteins including mortalin and Grp78 to disrupt the HPV-E7 oncoprotein, potentially preventing precancerous cells from developing into cancer.
3
Cervical cancer remains a major health burden in India, accounting for roughly 77,348 deaths and 123,907 new cases annually due to high-risk HPV types 16 and 18.